Citigroup Maintains Neutral on Haemonetics, Raises Price Target to $92
Haemonetics Corporation
Haemonetics Corporation HAE | 0.00 |
Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:
HAE) with a Neutral and raises the price target from $79 to $92.
